Mechanism and Clinical Positioning of Leflunomide: A Comprehensive Guide to csDMARDs

　　1.Drug Classification and Properties

　　Leflunomide is classified as a conventional synthetic Disease-Modifying Antirheumatic Drug(csDMARD).Unlike potent immunosuppressants such as Cyclosporine,it functions primarily as an immunomodulator.This distinction allows it to regulate overactive immune responses while preserving fundamental host defense mechanisms.

　　2.Pharmacological Mechanism

　　Leflunomide acts as a prodrug,metabolized in vivo to its active metabolite,A771726.Its core mechanism involves the selective inhibition of dihydroorotate dehydrogenase(DHODH),thereby blocking the de novo synthesis pathway of pyrimidines.Since activated T-cells and B-cells rely heavily on de novo pyrimidine synthesis for proliferation,Leflunomide achieves"selective inhibition"of lymphocytes.In contrast,other cells like intestinal epithelial cells can utilize salvage pathways for pyrimidine synthesis,explaining why Leflunomide modulates rather than broadly suppresses the immune system.

　　3.Clinical Positioning and Applications

　　Leflunomide is primarily indicated for Rheumatoid Arthritis(RA)and Psoriatic Arthritis(PsA).Clinically,it serves as an alternative or add-on therapy to Methotrexate.It is considered a first-line option for patients intolerant or unresponsive to Methotrexate.Additionally,it is utilized off-label for the treatment of Lupus Nephritis.

　　4.Comparative Advantages

　　Compared to Methotrexate,Leflunomide carries a lower risk of interstitial lung disease,though both share similar hepatotoxicity profiles.When compared to biologics like Adalimumab,Leflunomide has a slower onset of action(typically 4–6 weeks)but offers superior cost-effectiveness.Furthermore,unlike JAK inhibitors(e.g.,Tofacitinib),Leflunomide does not appear to increase the risk of thromboembolism,providing a safer profile for specific patient populations.

　　5.Dosing and Monitoring

　　The recommended regimen includes a loading phase of 100 mg daily for 3 days,followed by a maintenance dose of 20 mg daily.Due to its long half-life(approximately 14 days),monthly monitoring of liver function tests and complete blood counts is essential.Upon discontinuation,cholestyramine washout may be required to expedite drug elimination due to the extended pharmacokinetic profile.